Limits...
Troxipide in the management of gastritis: a randomized comparative trial in general practice.

Dewan B, Balasubramanian A - Gastroenterol Res Pract (2010)

Bottom Line: Patients receiving Troxipide also showed a greater improvement in the VAS scores for abdominal pain, bloating, and heartburn (P < .01).Both the drugs were found to be well tolerated.Conclusion.

View Article: PubMed Central - PubMed

Affiliation: Medical Services Department, Zuventus Healthcare Ltd, 5119, 'D' Wing, Oberoi Garden Estates, Chandivali, Mumbai 400072, India.

ABSTRACT
Background. A trial of empirical acid-suppressive therapy is the usual practice for most patients with symptoms of gastritis in primary care. Aim. To assess the relative efficacy of Troxipide and Ranitidine in patients with endoscopic gastritis over a four-week period. Methods. In all, 142 patients were randomized to Troxipide (100 mg tid) or Ranitidine (150 mg bid) for a period of four weeks. The severity of the signs of endoscopic gastritis at baseline and week 4 using a four-point scale and the subjective symptom severity at baseline and week 2 & week 4 using a Visual analog scale (VAS) were documented. Results. Troxipide was found to be superior to Ranitidine for both, the complete resolution and improvement of endoscopic gastritis. Higher proportion of patients showed complete healing of erosions (88.14%), oozing (96.77%), and edema (93.88%) with Troxipide as compared to Ranitidine (P < .01). Patients receiving Troxipide also showed a greater improvement in the VAS scores for abdominal pain, bloating, and heartburn (P < .01). Both the drugs were found to be well tolerated. Conclusion. In patients with endoscopic gastritis, Troxipide, with its superior rate of improvement, resolution of signs, and subjective clinical symptoms, can be considered as an alternative to the commonly used antisecretory agents.

No MeSH data available.


Related in: MedlinePlus

Clinical symptom improvement in endoscopic gastritis with Troxipide and Ranitidine. Percentage of patients at each followup period (week 2 and 4) reporting clinical symptom improvement (a reduction in the VAS score of at least 20 points from baseline to followup) for abdominal pain, bloating, and heartburn with Troxipide and Ranitidine (*P < .05 and **P < .01).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2992815&req=5

fig2: Clinical symptom improvement in endoscopic gastritis with Troxipide and Ranitidine. Percentage of patients at each followup period (week 2 and 4) reporting clinical symptom improvement (a reduction in the VAS score of at least 20 points from baseline to followup) for abdominal pain, bloating, and heartburn with Troxipide and Ranitidine (*P < .05 and **P < .01).

Mentions: Some positive change in the severity of the subjective symptom was seen in all the 142 patients participating in the study. However, the reduction in the mean VAS score, at the end of week 2 and week 4, were found to be superior with Troxipide as compared to Ranitidine (Table 3), especially for abdominal pain, bloating, and heartburn (P < .01). Symptoms improvement (a reduction in the VAS score of at least 20 points from baseline to followup) was seen in a higher proportion of patients with Troxipide as compared to Ranitidine in case of abdominal pain, bloating, and heartburn (Figure 2).


Troxipide in the management of gastritis: a randomized comparative trial in general practice.

Dewan B, Balasubramanian A - Gastroenterol Res Pract (2010)

Clinical symptom improvement in endoscopic gastritis with Troxipide and Ranitidine. Percentage of patients at each followup period (week 2 and 4) reporting clinical symptom improvement (a reduction in the VAS score of at least 20 points from baseline to followup) for abdominal pain, bloating, and heartburn with Troxipide and Ranitidine (*P < .05 and **P < .01).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2992815&req=5

fig2: Clinical symptom improvement in endoscopic gastritis with Troxipide and Ranitidine. Percentage of patients at each followup period (week 2 and 4) reporting clinical symptom improvement (a reduction in the VAS score of at least 20 points from baseline to followup) for abdominal pain, bloating, and heartburn with Troxipide and Ranitidine (*P < .05 and **P < .01).
Mentions: Some positive change in the severity of the subjective symptom was seen in all the 142 patients participating in the study. However, the reduction in the mean VAS score, at the end of week 2 and week 4, were found to be superior with Troxipide as compared to Ranitidine (Table 3), especially for abdominal pain, bloating, and heartburn (P < .01). Symptoms improvement (a reduction in the VAS score of at least 20 points from baseline to followup) was seen in a higher proportion of patients with Troxipide as compared to Ranitidine in case of abdominal pain, bloating, and heartburn (Figure 2).

Bottom Line: Patients receiving Troxipide also showed a greater improvement in the VAS scores for abdominal pain, bloating, and heartburn (P < .01).Both the drugs were found to be well tolerated.Conclusion.

View Article: PubMed Central - PubMed

Affiliation: Medical Services Department, Zuventus Healthcare Ltd, 5119, 'D' Wing, Oberoi Garden Estates, Chandivali, Mumbai 400072, India.

ABSTRACT
Background. A trial of empirical acid-suppressive therapy is the usual practice for most patients with symptoms of gastritis in primary care. Aim. To assess the relative efficacy of Troxipide and Ranitidine in patients with endoscopic gastritis over a four-week period. Methods. In all, 142 patients were randomized to Troxipide (100 mg tid) or Ranitidine (150 mg bid) for a period of four weeks. The severity of the signs of endoscopic gastritis at baseline and week 4 using a four-point scale and the subjective symptom severity at baseline and week 2 & week 4 using a Visual analog scale (VAS) were documented. Results. Troxipide was found to be superior to Ranitidine for both, the complete resolution and improvement of endoscopic gastritis. Higher proportion of patients showed complete healing of erosions (88.14%), oozing (96.77%), and edema (93.88%) with Troxipide as compared to Ranitidine (P < .01). Patients receiving Troxipide also showed a greater improvement in the VAS scores for abdominal pain, bloating, and heartburn (P < .01). Both the drugs were found to be well tolerated. Conclusion. In patients with endoscopic gastritis, Troxipide, with its superior rate of improvement, resolution of signs, and subjective clinical symptoms, can be considered as an alternative to the commonly used antisecretory agents.

No MeSH data available.


Related in: MedlinePlus